These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6376028)

  • 21. Extrapancreatic effects of sulfonylureas. Potentiation of insulin action through post-binding mechanisms.
    Lockwood DH; Maloff BL; Nowak SM; McCaleb ML
    Am J Med; 1983 Jan; 74(1A):102-8. PubMed ID: 6401922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of three sulfonylureas on in vivo insulin action.
    Sato J; Ohsawa I; Oshida Y; Fukuharu M; Hu XC; Tamagawa T; Sato Y
    Arzneimittelforschung; 2001; 51(6):459-64. PubMed ID: 11455676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Porin proteins in mitochondria from rat pancreatic islet cells and white adipocytes: identification and regulation of hexokinase binding by the sulfonylurea glimepiride.
    Müller G; Korndörfer A; Kornak U; Malaisse WJ
    Arch Biochem Biophys; 1994 Jan; 308(1):8-23. PubMed ID: 8311478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
    J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents.
    Home PD; Pacini G
    Diabetes Obes Metab; 2008 Sep; 10(9):699-718. PubMed ID: 17825080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The hypoglycemic effect of AH-9].
    Jiang Z; Xie M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Aug; 15(4):235-41. PubMed ID: 8168201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
    J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Insulin resistance in type 2 diabetes. Receptor and post-receptor aspects].
    Purrello F; Trischitta V; Vigneri R
    Minerva Endocrinol; 1984; 9(2):221-8. PubMed ID: 6390135
    [No Abstract]   [Full Text] [Related]  

  • 30. Insulino-mimetic and anti-diabetic effects of vanadium compounds.
    Srivastava AK; Mehdi MZ
    Diabet Med; 2005 Jan; 22(1):2-13. PubMed ID: 15606684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adipose tissue compensates for defect of phosphatidylinositol 3'-kinase induced in liver and muscle by dietary fish oil in fed rats.
    Corporeau C; Foll CL; Taouis M; Gouygou JP; Bergé JP; Delarue J
    Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E78-E86. PubMed ID: 16339925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
    Müller G; Satoh Y; Geisen K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sulfonylureas on the actions of insulin and insulin-mimickers: potentiation of stimulated hexose transport in adipocytes.
    Maloff BL; Drake L; Riedy DK; Lockwood DH
    Eur J Pharmacol; 1984 Sep; 104(3-4):319-26. PubMed ID: 6389157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats.
    Salhanick AI; Konowitz P; Amatruda JM
    Diabetes; 1983 Mar; 32(3):206-12. PubMed ID: 6337899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in plasma amino acids levels and "in vivo" gluconeogenesis from alanine in rats chronically treated with sulfonylureas.
    Alemany M; Palou A; Codina J; Herrera E
    Diabete Metab; 1978 Sep; 4(3):181-6. PubMed ID: 101403
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
    Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appraisal of the extrapancreatic actions of sulfonylureas.
    Feldman JM; Lebovitz HE
    Arch Intern Med; 1969 Mar; 123(3):314-22. PubMed ID: 4885677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.